Positive Phase 2 Trial Results for VidoCa in PMS Bolster Buy Rating for Immunic

Analyst Faisal Khurshid of Leerink Partners reiterated a Buy rating on Immunic (IMUX – Research Report), retaining the price target of $6.00.

Faisal Khurshid has given his Buy rating due to a combination of factors related to Immunic’s recent Phase 2 trial results for VidoCa in progressive multiple sclerosis (PMS). The promising data, particularly regarding disability progression, have been positively received by key opinion leaders (KOLs) in the neurology field. Despite some concerns about the primary endpoint related to brain volume, the KOLs emphasized the significance of the disability progression results, which are crucial from both clinical and regulatory perspectives.
Additionally, the potential for VidoCa to provide a safe and effective oral treatment option for PMS is seen as highly attractive. The KOLs expressed optimism about the drug’s ability to address both inflammatory and progressive aspects of the disease, which is considered a significant achievement in the treatment of multiple sclerosis. This positive outlook on the Phase 2 data and the potential for further development into a Phase 3 study support Khurshid’s Buy rating for Immunic’s stock.

In another report released on May 1, H.C. Wainwright also reiterated a Buy rating on the stock with a $10.00 price target.